SCHEMBL10243023

SCHEMBL10243023

CCCCNC(=O)Nc1cccc(-c2ccco2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN7 P35236 4/20 0.64
CCR3 P51677 1/20 0.55
EPHX1 P07099 7/20 0.55
CDK8 P49336 1/20 0.53
ALDH1A1 P00352 3/20 0.51
HTT P42858 1/20 0.51
MAPT P10636 2/20 0.51
MEN1 O00255 2/20 0.51
POLB P06746 2/20 0.51
BLM P54132 2/20 0.51
KMT2A Q03164 2/20 0.51
KDM4E B2RXH2 1/20 0.51
THRB P10828 1/20 0.51
HPGD P15428 1/20 0.51
APEX1 P27695 1/20 0.51
RECQL P46063 1/20 0.51
CACNA1B Q00975 1/20 0.51
APBA1 Q02410 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
EPHX2 P34913 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10242991 0.82 SMN1; SMN2 (0.60) ALDH1A1HTTMAPTMEN1KMT2A
SCHEMBL10242939 0.80 SMN1; SMN2 (0.65) PTPN7ALDH1A1HTTMAPTMEN1
SCHEMBL10242902 0.78 PRMT6 (0.51) PTPN7ALDH1A1MAPTMEN1POLB
SCHEMBL10242942 0.78 PTGS2 (0.54) PTGS2
SCHEMBL14050083 0.78 CDK8 (0.56) PTPN7EPHX1CDK8ALDH1A1HTT
SCHEMBL10243027 0.77 SMN1; SMN2 (0.59) ALDH1A1HTTMAPTMEN1POLB
SCHEMBL6064818 0.76 EPHX1 (0.66) EPHX1CDK8ALDH1A1HTTMAPT
SCHEMBL10192072 0.76 MEN1 (0.69) EPHX1ALDH1A1HTTMAPTMEN1
SCHEMBL4320689 0.76 KEAP1 (0.59) ALDH1A1HTTMAPTMEN1POLB
SCHEMBL6438910 0.76 EPHX1 (0.83) EPHX1ALDH1A1HTTMAPTEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 PTPN7 542/4885CCR3 2548/4885EPHX1 1924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.